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Objectives The impact of individual antiarrhythmic drugs (AADs) on mortality and hospital stay in atrial fibrillation (AF) was
evaluated.
Background Cardiovascular (CV) outcomes in AF patients receiving pharmacologic rhythm control therapy have not been
compared with rate control therapy on the basis of AAD selection.
Methods We compared CV outcomes in the AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) trial in
subgroups defined by the initial AAD selected with propensity score matched subgroups from the rate arm (Rate).
Results Seven hundred twenty-nine amiodarone patients, 606 sotalol patients, and 268 Class 1C patients were matched. The
composite outcome of mortality or cardiovascular hospital stays (CVH) showed better outcomes with Rate compared
with amiodarone (hazard ratio [HR]: 1.18, 95% confidence interval [CI]: 1.03 to 1.36, p  0.02), sotalol (HR: 1.32,
95% CI: 1.13 to 1.54, p  0.001), and Class 1C (HR: 1.22, 95% CI: 0.97 to 1.56, p  0.10). There was a nonsignifi-
cant increase in mortality with amiodarone (HR: 1.20, 95% CI: 0.94 to 1.53, p  0.15) with the risk of non-CV death
being significantly higher with amiodarone versus Rate (HR: 1.11, 95% CI: 1.01 to 1.24, p  0.04). First CVH event
rates at 3 years were 47% for amiodarone, 50% for sotalol, and 44% for Class 1C versus 40%, 40%, and 36%, re-
spectively, for Rate (amiodarone HR: 1.20, 95% CI: 1.03 to 1.40, p  0.02, sotalol HR: 1.364, 95% CI: 1.16 to 1.611,
p  0.001, Class 1C HR: 1.24, 95% CI: 0.96 to 1.60, p  0.09). Time to CVH with intensive care unit stay or death
was shorter with amiodarone (HR: 1.22, 95% CI: 1.02 to 1.46, p  0.03).
Conclusions In AFFIRM, composite mortality and CVH outcomes differed for Rate and AADs due to differences in CVH; CVH
event rates during follow-up were high for all cohorts, but they were higher for all groups on AADs. Death, inten-
sive care unit hospital stay, and non-CV death were more frequent with amiodarone. (Atrial Fibrillation Follow-Up
Investigation of Rhythm Management; NCT00000556) (J Am Coll Cardiol 2011;58:1975–85) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.036Atrial fibrillation (AF) is the most prevalent tachyarrhyth-
mia and is associated with increased mortality, stroke, and
recurrent hospital stays (1,2). Health care resource con-
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due to hospital stay, is among the
highest for cardiovascular (CV)
diagnoses, but the patterns of
these hospital stays and their re-
lationship to individual therapeutic
choices in AF have not been evalu-
ated (3). The AFFIRM (Atrial Fi-
brillation Follow-Up Investigation
of Rhythm Management) trial was
conducted to examine 2 treatment
strategies for AF, namely rate con-
trol or rhythm control (4,5). All-
cause mortality, the primary out-
come measure, showed a trend
toward excess mortality in the rhythm control arm. The antiar-
rhythmic drugs (AADs) used in the rhythm arm have been cited
as a potential cause of the excess mortality (6). Despite concerns
with regard to their safety, most of the AADs used in the
AFFIRM trial remain widely used in clinical practice.
The impact of individual AADs on mortality and hospital
stay outcomes in the AFFIRM population in relation to rate
control has not been available. In part, this was related to
the intent of the AFFIRM investigators to test the treat-
ment strategy hypothesis rather than individual drug ther-
apies. In this report, we examined the impact on outcomes
of the selection of amiodarone, sotalol, or a Class 1C
antiarrhythmic agent (flecainide or propafenone) as the first
AAD, compared with a rate strategy in the AFFIRM study.
The AADs were selected for this analysis on the basis of
current widespread clinical usage. To address the nonran-
dom nature of drug selection in the rhythm arm, we
employed propensity score matching derived from 64 base-
line patient characteristics deemed to affect antiarrhythmic
selection. Propensity score matching has not been employed
to assess individual drug outcomes in the AFFIRM trial (7).
We compared mortality and hospital stay outcomes in
patient subgroups defined by each type of AAD selected as
first therapy with propensity score matched subgroups from
the rate control arm.
Methods
Patient Selection in the AFFIRM Trial
The AFFIRM trial recruited consenting patients who had AF
that was likely to be recurrent, warranted therapy, and had risk
factor(s) for stroke. Patients were candidates for at least 2 drugs
within each strategy and for anticoagulation (4).
Primary Objective of Analysis
Reassessment of clinical outcomes by initial AAD therapy.
The primary objective was to reassess clinical outcomes in
the AF population enrolled in the AFFIRM study by initial
AAD therapy with a composite principal outcome and its
individual components. The principal outcome was a com-
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
CI  confidence interval
CV  cardiovascular
CVH  cardiovascular
hospital stay(s)
HR  hazard ratio
ICU  intensive care unit
Rate  rate control
strategy armposite of mortality or first cardiovascular hospital stay(CVH). Individual components (all-cause mortality and
CVH) were also examined, as were subsets of both CVH
and all-cause mortality (8). The AAD subgroups were
compared with propensity score matched rate subgroups
(Rate) and included: 1) initial amiodarone therapy (amio-
darone cohort); 2) initial sotalol (sotalol cohort); and 3)
initial Class 1C drug (flecainide or propafenone, Class 1C
cohort).
Propensity score matched subgroups were selected
from the rate control strategy arm (Rate) for each AAD
cohort. The score was derived with 62 baseline patient
characteristics from the AFFIRM database deemed a
priori to potentially affect AAD selection. Two additional
characteristics that were determined to be important to
achieve balanced cohorts (left ventricular ejection frac-
tion, and history of coronary artery disease) were added in
a second step (Table 1).
Secondary Objectives
Relating outcomes to clinical and treatment factors. The
severity of CVH was characterized by acuity of hospital stay
on the basis of concomitant intensive care unit (ICU) stay,
CV procedures, CV interventions, or emergency room
visits. Outcomes in AAD subgroups were related to patient
characteristics, underlying disease state, clinical events, and
treatment strategy.
Study Outcomes and Definitions
The principal outcome for this analysis was a composite
outcome: the first of death from any cause or a CVH. A
CVH was defined as a hospital admission for CV reasons
(per investigator) or for non-CV reasons but with a CV
event occurring during the same follow-up interval. Exact
dates were available for death but not for hospital admission
or discharge. The midpoint of the previous follow-up visit
and the follow-up visit when the hospital stay was reported
were used to estimate event time for CVH. Investigators
recorded total number of hospital days and total number of
ICU days. Visits occurred at 2 months after randomization
and every 4 months thereafter. Patients who did not
experience CVH or death were censored at the last
follow-up visit. For death alone, follow-up information
from a vital status sweep (telephone contact with all subjects
and national death index scan) at the end of the study was
used to determine censoring date.
Statistical Methods and Analytical Techniques
Propensity score and establishment of matched cohorts.
The goal of development of propensity score matched
cohorts was to account for possible confounding variables
that might be related to drug selection, because the patients
were not assigned randomly to specific initial drug therapy
in the AFFIRM trial.
Selection of covariates. Propensity score was calculated
separately for each AAD subgroup (amiodarone, sotalol, or
Class 1C). Four patients received more than 1 AAD and
e
D
c
ular; m
1977JACC Vol. 58, No. 19, 2011 Saksena et al.
November 1, 2011:1975–85 CV Outcomes of AADs in the AFFIRM Trialwere excluded. The propensity score model used data from
AFFIRM patients randomized to rhythm control. Identical
baseline explanatory variables were included in each model
and were prospectively determined by consensus before data
analysis (Table 1). This model included explanatory vari-
ables that might be considered by clinicians when selecting
an AAD, including demographic data, clinical characteris-
tics of patients, treating physicians (cardiologists or other),
centers, and study design factors. Patients in the first AAD
substudy had their first AAD randomly assigned, so partic-
ipation in first AAD sub-study was included as a variable
(9). A stepwise model reduction procedure was used to
produce a parsimonious model for each propensity score
equation. After initial cohort construction, imbalances in 2
additional variables, coronary artery disease and left ventric-
ular ejection fraction, were identified; these items were
Covariates Used in Propensity Score ModelTable 1 Covariates Used in Propensity Scor
Age
Sex
Year of randomization
Site
FADS site
History of myocardial infarction
History of pulmonary disease
History of intracranial hemorrhage
History of congestive heart failure, congestive heart failure
History of cardiomyopathy
History of valvular heart disease
History of congenital heart disease
History of angina
History of diabetes
History of hepatic or renal disease
History of symptomatic brady/atrioventricular block
History of resuscitated cardiac arrest
History of stroke/transient ischemic attack
History of peripheral vascular disease
History of systemic embolism
History of hemorrhage or coagulopathy
History of thyroid disease/specific drugs—thyroid replacem
History of carotid disease
Symptoms constellations are
1. Chest pain
2. Diaphoresis, fatigue, panic, dizziness, syncope
3. Diuresis
4. Dyspnea, edema, orthopnea, paroxysmal nocturnal dys
5. Fast heart rate, palpitations
AF symptoms frequency
First AF episode
Duration of qualifying AF episode(s)
Hospitalized for qualifying episode
Cardioverted for qualifying episode(s)
Current ventricular/max HR during AF 100 beats/min
List of covariates used in propensity score model. Please note that m
pressure (SBP).
AAD  antiarrhythmic drug; AF  atrial fibrillation; BMI  body mas
 first antiarrhythmic drug substudy; HR heart rate; LV left ventric
SBP  systolic blood pressure.added to the model in a second step. cModel building. Proc GLIMMIX in SAS (version 9.2, SAS
Institute, Cary, North Carolina) was used for building the
propensity-matched cohorts. Each model considered all ex-
planatory variables in Table 1. Site was included as a fixed effect
for this step. The functional form of response was assessed for
continuous variables to determine whether transformation was
necessary (10). Then, the model was run twice, with site as a
fixed and then as a G-sided (generalized) random effect. These
models were compared for evidence of extra binomial variabil-
ity at the investigator site level. Risk score was calculated for
each patient in the rate subgroup, and the VMATCH algo-
rithm (Zentrum fur Bioinformatik, Hamburg, Germany) was
used to construct the cohorts (7). Matching was 1:1 between
ach AAD cohort and the rate cohort.
escriptive reporting. Once the propensity score matched
ohorts were established, baseline demographic and clinical
del
Primary cardiac diagnosis
Coronary artery disease
NYHA
Current CCS angina class
Failed any AAD
Number of AAD failures
Failed amiodarone
Failed disopyramide
ollment Failed flecainide
Failed moricizine
Failed procainamide
Failed propafenone
Failed quinidine
Failed sotalol
Failed other AAD
Previous other CV procedure
Previous percutaneous coronary interventions
Previous coronary artery bypass grafting
Previous thrombolytic therapy
LV ejection fraction
Beta stimulant
Theophylline
Diuretic
Beta-blockers
Diltiazem
Verapamil
BMI
SBP
FADS patient
Other cardiac neurologic interaction
imputation was used for body mass index (BMI) and systolic blood
; CCS  Canadian Cardiovascular Society; CV  cardiovascular; FADS
axmaximum; NYHA New York Heart Association functional class;e Mo
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CV Outcomes of AADs in the AFFIRM Trial November 1, 2011:1975–85AFFIRM publication (5). Tests for differences across
atched cohorts were conducted (Fisher exact or chi-square
or categorical variables, analysis of variance or Wilcoxon for
ontinuous variables).
rincipal Outcome
he principal outcome analyzed was a comparison of event
ime with the log-rank test on an intention-to-treat basis,
imilar to the primary AFFIRM analysis. Unadjusted
aplan-Meier survival curves were examined for each
ropensity-score matched cohort pair. Proportional hazards
odels were used to obtain hazard ratios (HRs) and 95%
onfidence intervals (CIs) and to determine the effect in
linically important subgroups.
ensitivity analyses. To determine the impact of treatment
strategy-related hospital stays, (e.g., cardioversions) and
further define acuity of CVH, we repeated the analysis with
a composite of death and first hospital stay requiring ICU
stay. To evaluate the propensity score methodology, a Cox
proportional hazards model with a frailty term for site was
used.
Results
Patient population. Seven hundred twenty-nine AF pa-
tients initially received amiodarone therapy, 606 received
initial sotalol therapy, and 268 received either initial flecain-
ide or propafenone. The clinical characteristics of these 3
AAD cohorts on the basis of initial drug therapy selection
are shown in Table 2. The AAD cohorts were generally
well-matched. Patients were usually elderly, predominantly
male, and had recurrent AF associated with cardiac disease.
The amiodarone cohort had a slight excess of men, com-
pared with its matched Rate cohort (67.4% vs. 61.3%,
respectively). More patients in the sotalol cohort had a
history of angina, compared with Rate (11.1% vs.
6.9%).There were no other significant differences. The C
statistic for the 3 propensity models were 0.814 for amio-
darone, 0.837 for sotalol, and 0.837 for Class 1C subgroups.
Outcomes analysis. HRs and 95% CIs for the overall com-
parison (rhythm compared with rate) in the AFFIRM trial and
individual AAD subgroups with the matched rate cohort are
shown for the composite principal outcome of mortality and
first CVH in Figure 1. All AAD cohorts had inferior
principal outcomes, compared with Rate (HR for amioda-
rone: 1.18, 95% CI: 1.03 to 1.36, p  0.02; HR for sotalol:
1.32, 95% CI: 1.13 to 1.54, p  0.001; and HR for Class
1C: 1.22, 95% CI: 0.97 to 1.56, p  0.10). In the smaller
Class 1C cohort, this difference did not reach statistical
significance. Figure 2 shows the individual components of
the composite endpoint. Risk of CVH was increased for all
3 AAD cohorts (amiodarone HR: 1.20, 95% CI: 1.03 to
1.40, p 0.05; sotalol HR: 1.36, 95% CI: 1.16 to 1.61, p
0.001; and Class 1C HR: 1.24, 95% CI: 0.96 to 1.64, p 
0.09, compared with Rate). Ninety-one percent of amioda-
rone patients, 88% of sotalol patients, and 78% of Class 1Cpatients were receiving the initially selected drug at first
CVH. There was no increased mortality risk for sotalol and
Class 1C cohorts, but an increase in risk was observed for
amiodarone (HR: 1.20, 95% CI: 0.94 to 1.53, p  0.15),
compared with Rate, which was not statistically significant.
Time to first CVH was shorter for all AADs, compared
with Rate. First CVH event rates at 3 years were 47% for
amiodarone, 50% for sotalol, and 44% for Class 1C com-
pared with 40%, 40%, and 36%, respectively, for the
matched Rate cohorts. The CV mortality did not differ
between Rate and any of the AAD cohorts (p  0.15 for all
comparisons). There was an increased risk of noncardiovas-
cular mortality with amiodarone (HR: 1.11, 95% CI: 1.01 to
1.24, p  0.04) but not with sotalol or Class 1C drugs,
compared with Rate. However, deaths attributable to cancer
or pulmonary causes were comparable across each cohort.
A composite of death or ICU hospital stays showed
moderately increased risk with amiodarone (HR: 1.22, 95%
CI: 1.02 to 1.46, p  0.03) but not with sotalol or Class 1C
agents (HR: 1.06, 95% CI: 0.87 to 1.30, p 0.56, and HR:
1.07, 95% CI: 0.78 to 1.46, p  0.67, respectively),
compared with Rate (Fig. 3A). There was no difference in
time to ICU hospital stays for sotalol and Class 1C,
compared with Rate, but a nonsignificant increased risk was
noted for amiodarone (HR: 1.18, 95% CI: 0.95 to 1.47, p
0.14) (Fig. 3B). All-cause hospital stays were increased in
amiodarone compared with Rate (HR: 1.19, 95% CI: 1.05
to 1.35, p 0.008) and in sotalol compared with Rate (HR:
.22, 95% CI: 1.06 to 1.41, p  0.005). There was no
increased risk of all-cause hospital stay with Class 1C
compared with Rate.
Concomitant beta-blocker therapy did not alter outcomes
for either sotalol or Class 1C cohorts for either mortality or
CVH risk (CVH for sotalol HR: 1.09, 95% CI: 0.89 to
1.34, for death HR: 1.15, 95% CI: 0.81 to 1.63; CVH for
Class 1C HR: 0.75, 95% CI: 0.60 to 1.03), for death HR:
0.65, 95% CI: 0.40 to 1.07). Amiodarone-Rate cohort
patients who were concomitantly taking beta-blockers had
an increased mortality risk (CVH risk for amiodarone HR:
1.06, 95% CI: 0.90 to 1.25, for death HR: 1.53, 95% CI:
1.16 to 2.02). There was no evidence of a treatment–
digoxin interaction for the principal outcome. Time-
dependent digoxin use was significantly associated with
CVH in the amiodarone-Rate cohorts (HR: 1.43, 95% CI:
1.21 to 1.68) and in the Class 1C-Rate cohorts (HR: 1.36,
95% CI: 1.04 to 1.77) but not in the sotalol-Rate cohorts
(HR: 1.15, 95% CI: 0.96 to 1.37). After adjusting for
time-dependent digoxin use, AADs still increased the risk
of CVH (HR for amiodarone: 1.34, 95% CI: 1.13 to 1.57,
HR for sotalol: 1.40, 95% CI: 1.17 to 1.67, compared with
matched rate patients; HR for Class 1C: 1.34, 95% CI: 1.03
to 1.75, compared with the respective AAD rate-matched
patients). The increased risk of CVH or death was consis-
tent across clinically important subgroups including coro-
nary disease, female sex, and age for amiodarone and sotalol
patients, presence of thyroid disease only in amiodarone
Baseline Patient Characteristics for Entire Rate Cohort in AFFIRMTable 2 Baseline Patient Characteristics for Entire Rate Cohort in AFFIRM
Overall Rate
(Original)
(n  2,027)
Rate
(PS Matched)
(n  729)
Amiodarone
(PS Matched)
(n  729)
p
Value
Rate
(PS Matched)
(n  606)
Sotalol
(PS Matched)
(n  606)
p
Value
Rate
(PS Matched)
(n  268)
Class 1C
(PS Matched)
(n  268)
p
Value
Age, yrs 69.8 8.91 69.7 8.79 70.3 9.2 0.21 70.5 8.4 69.6 8.8 0.06 68.6 9.3 68.6 8.9 0.94
Female 823 (40.6%) 282 (38.7%) 238 (32.6%) 0.02 234 (38.6%) 227 (37.5%) 0.68 144 (53.7%) 140 (52.2%) 0.73
Ethnic minority group 241 (11.9%) 98 (13.4%) 78 (10.7%) 0.11 70 (11.6%) 57 (9.4%) 0.22 23 (8.6%) 24 (9.0%) 0.88
Predominant cardiac diagnosis 0.92 0.74 0.66
Coronary artery disease (MI, angina, and so on) 497 (24.5%) 228 (31.3%) 247 (33.9%) 165 (27.2%) 158 (26.1%) 28 (10.4%) 31 (11.6%)
Dilated cardiomyopathy 99 (4.9%) 53 (7.3%) 52 (7.1%) 22 (3.6%) 20 (3.3%) 5 (1.9%) 5 (1.9%)
Hypertension 1,045 (51.6%) 351 (48.1%) 342 (46.9%) 291 (48.0%) 315 (52.0%) 154 (57.5%) 156 (58.2%)
Valvular heart disease 98 (4.8%) 30 (4.1%) 28 (3.8%) 34 (5.6%) 34 (5.6%) 9 (3.4%) 15 (5.6%)
Other 23 (1.1%) 9 (1.2%) 7 (1.0%) 13 (2.1%) 9 (1.5%) 3 (1.1%) 1 (0.4%)
No apparent heart disease 265 (13.1%) 58 (8.0%) 53 (7.3%) 81 (13.4%) 70 (11.6%) 69 (25.7%) 60 (22.4%)
History of congestive heart failure 475 (23.4%) 223 (30.6%) 221 (30.3%) 0.91 121 (20.0%) 112 (18.5%) 0.51 27 (10.1%) 24 (9.0%) 0.66
Duration of qualifying AF 2 days 1,406 (69.4%) 519 (71.2%) 525 (72.1%) 0.7 410 (67.7%) 406 (67.0%) 0.81 175 (65.3%) 172 (64.2%) 0.79
First episode of AF (vs. recurrent episode)* 700 (35.8%) 260 (36.6%) 254 (34.8%) 0.48 223 (37.9%) 214 (35.3%) 0.35 78 (29.7%) 73 (27.2%) 0.54
Any pre-randomization failure of an antiarrhythmic drug 364 (18.0%) 146 (20.0%) 139 (19.1%) 0.64 83 (13.7%) 70 (11.6%) 0.26 60 (22.4%) 69 (25.7%) 0.36
Size of left atrium normal† 549 (35.3%) 196 (36.6%) 184 (33.5%) 0.28 175 (36.1%) 172 (35.9%) 0.96 94 (43.1%) 90 (41.9%) 0.79
LVEF† 54.9 13.1 49.4 14.8 48.7 16.9 0.71 57.4 12.1 56.7 11.0 0.64 58.5 11.6 61.4 8.4 0.08
Normal LVEF† 1,131 (74.9%) 326 (63.8%) 324 (61.6%) 0.46 374 (80.1%) 370 (79.4%) 0.8 190 (89.6%) 195 (89.9%) 0.94
Baseline CCS class
No angina 1,835 (90.5%) 637 (87.4%) 636 (87.2%) 0.98 558 (92.1%) 539 (88.9%) 0.12 256 (95.5%) 258 (96.3%) 0.9
Class I 135 (6.7%) 60 (8.2%) 62 (8.5%) 37 (6.1%) 56 (9.2%) 8 (3.0%) 7 (2.6%)
Class II or greater 57 (2.8%) 32 (4.4%) 31 (4.3%) 11 (1.8%) 11 (1.8%) 4 (1.5%) 3 (1.1%)
Baseline NYHA functional class
No CHF 1,618 (79.8%) 541 (74.2%) 532 (73.0%) 0.10 517 (85.3%) 526 (86.8%) 0.86 242 (90.3%) 240 (89.6%) 0.85
Class I 215 (10.6%) 81 (11.1%) 96 (13.2%) 76 (12.5%) 70 (11.6%) 16 (6.0%) 19 (7.1%)
Class II 158 (7.8%) 89 (12.2%) 71 (9.7%) 12 (2.0%) 9 (1.5%) 10 (3.7%) 9 (3.4%)
Class III 36 (1.8%) 18 (2.5%) 30 (4.1%) 1 (0.2%) 1 (0.2%) 0 (0.0%) 0 (0.0%)
Values are mean  SD or n (%). Baseline patient characteristics for entire Rate cohort in AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) trial (Overall Rate) and the 3 paired propensity (PS) matched cohorts for individual antiarrhythmic drugs
and matched rate control groups. The size of the left atrium was unknown in 185 of 3,311 cases, and left ventricular function (where normal was defined as left ventricular ejection fraction [LVEF]  0.50) was unknown in 279 of 3,311. Electrocardiogram information was
not used in PS models. *This information was not collected on the initial version of the data form and therefore was imputed for 143 patients. †Electrocardiograms were obtained in 3,311 of 4,060.
CHF  congestive heart failure; MI  myocardial infarction; other abbreviations as in Table 1.
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CV Outcomes of AADs in the AFFIRM Trial November 1, 2011:1975–85patients but in none of the subgroups examined for the
Class 1C patients. These results are detailed in the next
section.
CVH categorized by intensity, duration, and associated
procedures are tabulated in Table 3. There were substantially
more hospital stays of 3-day duration associated with
cardioversion in the amiodarone and sotalol cohorts than
matched rate cohorts. Cardioversion occurred at similar
rates in the matched Class 1C and Rate cohorts (7.2%).
Cardiovascular hospital stays with a length of stay of 3
days with a cardioversion procedure alone (without another
CV procedure, emergency room visits, or ICU stay [i.e.,
events that might reflect adherence to AF rhythm control
treatment strategy only]) constituted 6.1%, 6.1%, and 4.0%
of first CVH for amiodarone, sotalol, and Class 1C,
respectively. The corresponding rates in the matched Rate
cohorts were 1.9%, 1.6%, and 0.9%, respectively. Stroke,
embolism, and major bleeds accounted for only a minority
of first CVH in both AAD and rate cohorts (Table 3).
Warfarin use at first CVH or death was slightly but not
significantly higher in the rate cohorts.
Potential risk factors for CVH. Baseline historical char-
acteristics that increased risk of CVH with AAD, compared
Figure 1 Comparison of Composite Principal Outcome: Individu
Hazard ratios (HRs) and Kaplan-Meier survival analyses comparing individual antia
composite principal outcome (time to first cardiovascular hospital stay [CVH] or de
(CIs) (HR: rhythm drug/Rate); (B) propensity score matched Rate and amiodarone
(D) propensity score matched Rate and Class 1C subgroups. All AADs and matche
up, but all AADs studied had a higher risk of events during follow-up. LR  log ranwith matched Rate cohorts, are shown in Table 4. Female vsex was associated with increased risk in sotalol and Class
1C cohorts, compared with matched Rate cohorts, but this
was not observed in the amiodarone-Rate cohort compari-
son. A history of heart failure, coronary disease, and diabetes
at enrollment were associated with increased risk for CVH
in all AAD cohorts. Pulmonary disease at baseline was
associated with increased risk of CVH with amiodarone,
and age 75 years was associated with increased risk of CVH
ith sotalol. There was evidence of significant AAD–
omorbidity interactions only in the amiodarone cohort; age
75 years and thyroid disease were associated with increased
isk for amiodarone patients but not for their matched Rate
ounterparts. A significant increased risk for CVH was main-
ained for amiodarone and sotalol, compared with Rate,
espite adjustments for age, sex, or any of these comorbidities.
Time-dependent changes in clinical status that increased
isk of CVH are shown in Table 5. In the amiodarone
atient cohort, relapse from sinus rhythm to AF and
ncrease in New York Heart Association (NYHA) func-
ional class by 1 or more were associated with a 1.9- and
.7-fold increase in CVH risk, respectively. For sotalol,
elapse from sinus rhythm to AF, increase 1 in NYHA
unctional class, increase in angina class by 1 or more, and
Ds Versus Rate
ic drugs (AADs) with matched rate control strategy arm (Rate) cohorts for the
ndividual panels are shown as follows: (A) HRs and 95% confidence intervals
) subgroups; (C) propensity score matched Rate and sotalol subgroups; and
e cohorts show substantial event rates for the principal outcome during follow-al AA
rrhythm
ath). I
(Amio
d Rat
k.entricular rate increase 15 beats/min were all associated
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November 1, 2011:1975–85 CV Outcomes of AADs in the AFFIRM TrialFigure 2 Components of Principal Outcome—First CVH and Mortality: Individual AADs Versus Rate
(A) First CVH: individual AADs versus Rate. The HRs and Kaplan-Meier survival analyses comparing individual AADs with matched Rate cohorts for a component of princi-
pal outcome: time to first CVH. Individual panels are shown as follows: 1) HRs and 95% CIs (HR: rhythm drug/Rate); 2) propensity score matched Rate and Amio sub-
groups; 3) propensity score matched Rate and sotalol subgroups; 4) propensity score matched Rate and Class 1C subgroups. All AADs and matched Rate cohorts show
substantial event rates during follow-up, but all AADs studied had a significantly higher risk of a first CVH during follow-up. (B) Mortality: individual AADs versus Rate. The
HRs and Kaplan-Meier survival analyses comparing individual AADs with matched Rate cohorts for a component of principal outcome: time to death. Individual panels
are shown as follows: 1) HRs and 95% CIs (HR: rhythm drug/Rate); 2) propensity score matched Rate and Amio subgroups; 3) propensity score matched Rate and sota-
lol subgroups; and 4) propensity score matched Rate and Class 1C subgroups. Sotalol and Class 1C groups and matched rate cohorts show comparable event rates for
risk of death during follow-up, but there is a nonsignificant increase in mortality with Amio compared with its matched Rate cohort. Abbreviations as in Figure 1.
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CV Outcomes of AADs in the AFFIRM Trial November 1, 2011:1975–85Figure 3 Comparison of Secondary Composite Outcome—ICUH or Death: Individual AADs Versus Rate
(A) Secondary composite outcome (intensive care unit hospital stays [ICUH] or death): individual AADs versus Rate. The HRs and Kaplan-Meier survival analyses
comparing individual AADs with matched rate cohorts for secondary composite outcome: time to first ICUH or death. Individual panels are shown as follows: 1)
HRs and 95% CIs (HR: rhythm drug/Rate); 2) propensity score matched Rate and Amio subgroups; 3) propensity score matched Rate and sotalol subgroups; 4)
propensity score matched Rate and Class 1C subgroups. Composite outcome shows that time to ICUH or death was shorter with Amio but not with sotalol or
Class 1C versus Rate during follow-up. (B) Comparison of ICUH: individual AADs versus Rate. The HRs and Kaplan-Meier survival analyses comparing individual
AADs with matched rate cohorts for secondary outcome: time to first ICUH. Individual panels are shown as follows: 1) HRs and 95% CIs (HR: rhythm drug/Rate);
2) propensity score matched Rate and Amio subgroups; 3) propensity score matched Rate and sotalol subgroups; 4) propensity score matched Rate and Class
1C subgroups. Time to ICUH was comparable for sotalol and Class 1C groups, compared with matched Rate cohorts, but a nonsignificant increased risk was
seen with Amio compared with Rate during follow-up.
r event
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November 1, 2011:1975–85 CV Outcomes of AADs in the AFFIRM Trialwith increased risk for CVH. For Class 1C, ventricular rate
increase 15 beats/min was associated with increased risk.
Higher absolute ventricular rate (in steps of 15 beats/min)
was associated with increased risk for sotalol and Class 1C
patients. Overall, a higher NYHA functional class was
associated with increased risk for all cohorts and higher
angina class for amiodarone and Class 1C patients.
Discussion
Analyses of overall and secondary outcomes for the AF
population in the AFFIRM study have suggested no overar-
ching benefit of a particular strategy (5,11–13). There was,
however, a nonsignificant increase in mortality in the rhythm
arm with an excess in pulmonary and cancer deaths (5,14).
This finding raised the specter of AAD therapy-related mor-
tality risk. The impact of individual AAD selection on both
mortality and hospital stay, compared with Rate, has not been
available due to the investigator-determined process for AAD
selection, which makes unbiased comparisons challenging.
However, such an analysis is still relevant and potentially
informative, because most of these agents are currently in
widespread clinical use and still employed in clinical trials
(15,16).
Cardiovascular Hospital Stay Profiles in the Propensity Score-MatcIndiv du l Antiarrhythmic Drugs in the AFFIRM TrialTable 3 C rdiovascular Ho pital Stay Profiles in he PropensityIndividual Antiarrhythmic Drugs in the AFFIRM Trial
Amiodarone Rate
CVH 342 309
# fatal first CVH 13 (3.8%) 14 (4.5%)
CVH 3 days 96 (28.1%) 95 (30.7%
CVH 3 days  CV 40 (11.7%) 11 (3.6%)
CVH 3 days, CV, no ER/ICU 21 (6.1%) 6 (1.9%)
CVH 3 days 246 (71.9%) 214 (69.3%
ICU days first CVH 95 (27.8%) 84 (27.2%
Warfarin use at first CVH (% of CVH) 279 (81.6%) 275 (89.0%
Bleeds/stroke/embolic events (% of CVH) 42 (12.3%) 54 (17.5%
Warfarin use at above event (% of event) 31 (73.8%) 47 (87.0%
Values are n or n (%).
AFFIRM Atrial Fibrillation Follow-Up Investigation of Rhythm Management; CV cardiovascula
Relationship Between Baseline CharacteristicsTable 4 Relationship Between Baseline Cha
Amiodarone-Rate C
Baseline variable
Heart failure 1.63 (1.4–1.91)
Female 1.08 (0.92–1.27
Coronary artery disease 1.83 (1.57–2.14
Pulmonary disease 1.3 (1.08–1.58
Diabetes 1.62 (1.36–1.92
Thyroid disease 1.44 (1.16–1.79
Age 75 yrs 1.14 (0.97–1.35
Interactions with treatment
Rate control  age 75 yrs 0.93 (0.72–1.21
Amiodarone  age 75 yrs 1.35 (1.08–1.69
Rate  thyroid disease 1.10 (0.80–1.51
Amiodarone  thyroid disease 1.92 (1.43–2.59Values are hazard ratio (95% confidence interval). *p  0.001; †p  0.05; ‡To evaluate these agents individually, we employed propen-
sity score matching to permit comparative analysis with the
rate control patients (17). In this report, it produced highly
comparable Rate and AAD cohorts for demographic data,
disease status and severity, prior interventions, and therapy
(Table 1).
Major Findings of the Study
Clinical outcomes, especially CVH, are affected by initial
AAD selection. The present analysis demonstrates inferior
performance in the principal clinical outcome for the indi-
vidual AADs studied versus rate control for the AFFIRM
population. This difference in composite outcome was
largely due to excess and earlier CVH for each AAD.
Sotalol and Class 1C cohorts were comparable to Rate for
all-cause mortality. The HR comparing amiodarone with
Rate was very similar to the overall AFFIRM study result
for mortality risk with rhythm control, but in this small
matched cohort the power to see a significant difference was
low (30%). Initial amiodarone therapy was associated with
significantly increased risk of non-CV death and mortality
plus ICU hospital stay. The sotalol and Class 1C cohorts
were similar to Rate with respect to these outcomes,
atient Cohorts forre-Matched Patient Cohorts for
Sotalol Rate Class 1C Rate
310 252 126 111
11 (3.5%) 5 (2.0%) 3 (2.4%) 8 (7.2%)
82 (26.5%) 70 (27.8%) 41 (32.5%) 35 (31.5%)
35 (11.3%) 9 (3.6%) 12 (9.5%) 8 (7.2%)
19 (6.1%) 4 (1.6%) 5 (4.0%) 1 (0.9%)
228 (73.5%) 182 (72.2%) 85 (67.5%) 76 (68.5%)
66 (21.3%) 72 (28.6%) 32 (25.4%) 34 (30.6%)
273 (88.1%) 227 (90.1%) 108 (85.7%) 101 (91.0%)
28 (9.0%) 40 (15.9%) 18 (14.3%) 18 (16.2%)
17 (60.7%) 31 (77.5%) 12 (66.7%) 7 (38.9%)
; CVH cardiovascular hospital stay(s); ER emergency room visit; ICU intensive care unit stay.
isk of CVHristics and Risk of CVH
Sotalol-Rate Cohort Class 1C-Rate Cohort
1.55 (1.29–1.86)* 1.5 (1.08–2.08)†
1.23 (1.04–1.46)† 1.37 (1.06–1.78)†
1.4 (1.18–1.65)* 1.37 (1.01–1.85)†
1.07 (0.82–1.4) 1.23 (0.86–1.74)
1.29 (1.07–1.57)‡ 1.56 (1.13–2.15)‡
1.12 (0.88–1.43) 1.26 (0.92–1.73)
1.25 (1.05–1.5)† 1.1 (0.81–1.49)hed PSco
)
)
)
)
)
)and Rracte
ohort
*
)
)*
)‡
)*
)‡
)
)
)
)
)p  0.01.
in risk
pital st
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less serious events than those seen with amiodarone.
CVH was extremely common with AF therapies in the
AFFIRM trial. From our data, we can estimate overall
CVH risk for AF populations and its relation to therapy
selection during the period 1995 to 2001. Cardiovascular
hospital stay incidence ranged from 36% to 50% at 3 years
for rate and rhythm therapies. Cardiovascular hospital
stay rates in the AFFIRM Rate subgroups were similar to
those seen in the placebo (rate control therapies only) arm
of the ATHENA (A placebo-controlled, double-blind,
parallel-arm Trial to assess the efficacy of dronedarone
400 mg BID for the prevention of cardiovascular Hospi-
talization or death from any cause in patiENts with Atrial
fibrillation/atrial flutter) trial (36.3% at 2.5 years) (15).
Clinical characteristics and initial AAD selection rather
than treatment strategy influenced CVH risk. Potential
mechanisms proposed for increased CVH include hospi-
tal stays related to change in AAD therapy with associ-
ated cardioversion or possible higher warfarin discontin-
uation rates with potential complications (5,12). Our
analysis of CVH related solely to cardioversions for the
rhythm control strategy, although higher than in
matched Rate cohorts, demonstrated a fairly low inci-
dence in all AAD cohorts. Stoke, embolism, and major
bleeds also had a low incidence that was comparable in
the matched Rate cohorts. Longer hospital stays, ICU
stays, and other CV procedures constituted the bulk of
CVH, suggesting more serious clinical conditions. Dif-
ferences in CVH rates persisted across clinically impor-
tant subgroups, such as elderly persons, women, and
coronary disease patients.
CVH in AF: insights from the AFFIRM trial. CVH has
become a major endpoint for clinical trials. It can impact
treatment strategy recommendations and regulatory ap-
Relationship Between Time Dependent Changes in Clinical StatusTable 5 Relationship Between Time Dependent Changes in Clin
Amiodarone vs. Rate p Value
SR to AF 1.87 (1.40–2.50) 0.0001
NYHA functional class
I 1.82 (1.45–2.29) 0.0001
II 2.28 (1.78–2.93)
III 3.51 (2.42–5.09)
IV 7.44 (3.42–16.20)
Increase in NYHA functional class 1.72 (1.35–2.20) 0.0001
CHC
I 2.20 (1.68–2.89) 0.0001
II 3.57 (2.40–5.30)
III 3.73 (1.61–8.64)
IV 4.08 (1.29–12.88)
Increase in CHC 1.25 (0.87–1.80) 0.22
VR/15 beats/min 1.13 (1.04–1.24) 0.01
Increase in VR by 15 beats/min 1.25 (0.96–1.64) 0.1
Values are hazard ratio (HR) (95% confidence interval). HR for ventricular rate (VR) is the increase
CHC  Canadian Heart Association classification for angina pectoris; CVH  cardiovascular hosproval of new therapies but is rarely used in AF trials(15,18–20). CVH in AF are costly, with average costs
estimated to exceed $12,000/AF admission in the United
States and $3 billion in annual costs (21). Atrial fibrillation
hospital stays are widely assumed to be related to AF
recurrences, but such an assumption has neither been
critically verified and quantified, nor has the uniformity of
this risk been assessed across AF subpopulations or treat-
ments (22).
To date, small trials of nonpharmacologic therapies
and 1 large pharmacologic therapy trial have provided
some information about CVH in AF (15,18 –20). Anal-
ysis of the AFFIRM database provides important addi-
tional data from a large randomized controlled trial over
a long follow-up. CVH presaged mortality, but it was
unclear how these events related to treatment strategy
and clinical condition (12). Given the observations with
respect to ICU hospital stays, CVH are usually related to
serious morbidity, with treatment strategy-related hospi-
tal stays—such as for a change of drug therapy or for
cardioversion— being a relatively small component. Ex-
cess CVH events observed with the AADs evaluated are
associated with age, sex, and comorbidity status. There is
a residual excess CVH risk even after adjustment for
these historical factors, which is related to AAD use.
Additionally, CVH risk can be related to changes in
cardiovascular disease status longitudinally. Time-
dependent changes that impact risk can include either AF
relapses or worsening of major cardiovascular symptoms
of the underlying disease. We propose, on the basis of our
analysis, that both baseline patient characteristics and
time-dependent changes in clinical status contribute to
CVH risk. Any heart failure or coronary disease was
associated with increased risk in all 3 matched cohorts
but was more common in the amiodarone and matched
isk of CVHStatus and Risk of CVH
Sotalol vs. Rate p Value Class 1C vs. Rate p Value
1.76 (1.29–2.41) 0.001 1.11 (0.64–1.94) 0.71
1.35 (1.00–1.82) 0.0001 2.17 (1.30–3.63) 0.0001
1.81 (1.19–2.77) 1.95 (1.00–3.82)
3.72 (2.19–6.33) 4.23 (1.49–12.04)
5.61 (4.65–52.47) 22.45 (6.01–83.82)
1.98 (1.39–2.83) 0.001 1.25 (0.67–2.34) 0.48
1.26 (0.82–1.92) 0.49 2.58 (1.28–5.19) 0.001
1.62 (0.87–3.01) 5.42 (2.09–14.01)
2.20 (0.64–7.48) 6.37 (1.19–34.01)
1.96 (0.45–8.61) 28.74 (3.10–266.46)
2.35 (1.40–3.92) 0.01 0.90 (0.36–2.22) 0.81
1.10 (1.00–1.21) 0.05 0.99 (0.84–1.16) 0.9
1.58 (1.20–2.07) 0.01 1.62 (1.04–2.51) 0.03
associated with a 15-beat/min increase in VR.
ay; Sota  sotalol; SR  sinus rhythm; other abbreviations as in Table 1.and Rical
1Rate cohorts. An increase in heart failure or angina class
h
r
1985JACC Vol. 58, No. 19, 2011 Saksena et al.
November 1, 2011:1975–85 CV Outcomes of AADs in the AFFIRM Trialby 1 or more increased risk of CVH. These findings make
a strong case for baseline disease state variables and
change in clinical status leading to CVH.
Relapse from sinus rhythm to AF was also related to
CVH, suggesting failure of rhythm control as a potential
mechanism. Finally, specific interactions of antiarrhythmic
agents such as amiodarone with comorbidities such as
thyroid disease suggest additional mechanisms leading to
hospital stay. The reasons for CVH are multiple and
multifactorial. Atrial fibrillation patients have varying risk
for the principal outcome in this analysis on the basis of
these factors.
Study Limitations
Propensity score matching cannot correct for erroneous
omission or inclusion of variables that might have affected
AAD selection, but it is a significant improvement over
naïve subgroup analyses. Some of the hospital stays might
be the result of routine patient care for rhythm control
rather than for medical necessity, but these still occur in
current clinical practice. The AFFIRM study did not
capture detailed reasons for hospital stay or drug doses.
Exact dates of hospital stay were not collected, which results
in decreased precision in estimates of time to hospital stay
but probably not for the comparison of matched cohorts.
Conclusions
CV hospitalizations were common in AFFIRM with both
treatment strategies but more frequent with amiodarone,
sotalol and class 1C agents. The severity of this risk varied
with the individual AAD, patient characteristics and time
dependent changes in clinical status, but was largely unre-
lated to the rhythm treatment algorithm. Death, intensive
care unit hospital stay, and non-CV death were more
frequent with amiodarone.
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